Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PART1 - a Prospective Phase II Study to Evaluate the Impact of TP53 Gene Mutations in Patients With Preoperative Radiotherapy for T2 and T3 Rectal Cancer

NCT02140723 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT02140723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02140723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PART1 - a Prospective Phase II Study to Evaluate the Impact of TP53 Gene Mutations in Patients With Preoperative Radiotherapy for T2 and T3 Rectal Cancer
Lead sponsor
Medical University of Vienna
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2011
Completion date
December 31, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer